Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients

Summary

Probands with MCI are at high risk to develop Alzheimer´s dementia (AD). Simvastatin may lower the production of Amyloid, a hallmark of AD in the brain. The primary hypothesis of the study is that 60 mg Simvastatin significantly reduces the Clinical Dementia Rating -Sum of boxes (CDR-SOB) in individuals with MCI as compared to MCI receiving placebo or 20 mg Simvastatin

Timeline

Start

2008-12

Primary completion

2020-08-31

Completion

2021-02-28

Drugs

Indications